CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income	Accumulated Deficit	Total
Balance as of beginning of period at Dec. 31, 2020	$ 59	$ 499,715	$ 4	$ (399,783)	$ 99,995
Balance as of beginning of period (in shares) at Dec. 31, 2020	58,915,375
Stockholders' Equity
At the market offering, net of sales agent commission	$ 6	40,724			40,730
At the market offering, net of sales agent commission (in shares)	5,583,329
Exercise of stock options		248			248
Exercise of stock options (in shares)	88,888
Issuance of common stock for vested restricted stock units (in shares)	107,780
Issuance of common stock under employee stock purchase plan		431			431
Issuance of common stock under employee stock purchase plan (in shares)	74,847
Stock-based compensation expense		9,780			9,780
Change in fair value of investments			(4)		(4)
Net loss				(66,910)	(66,910)
Balance as of end of period at Jun. 30, 2021	$ 65	550,898		(466,693)	84,270
Balance as of end of period (in shares) at Jun. 30, 2021	64,770,219
Balance as of beginning of period at Dec. 31, 2020	$ 59	499,715	4	(399,783)	99,995
Balance as of beginning of period (in shares) at Dec. 31, 2020	58,915,375
Balance as of end of period at Dec. 31, 2021	$ 66	559,126		(542,388)	16,804
Balance as of end of period (in shares) at Dec. 31, 2021	65,500,275
Balance as of beginning of period at Mar. 31, 2021	$ 64	539,920	3	(430,195)	109,792
Balance as of beginning of period (in shares) at Mar. 31, 2021	63,805,108
Stockholders' Equity
At the market offering, net of sales agent commission	$ 1	6,020			6,021
At the market offering, net of sales agent commission (in shares)	837,257
Exercise of stock options		64			64
Exercise of stock options (in shares)	20,074
Issuance of common stock for vested restricted stock units (in shares)	107,780
Stock-based compensation expense		4,894			4,894
Change in fair value of investments			(3)		(3)
Net loss				(36,498)	(36,498)
Balance as of end of period at Jun. 30, 2021	$ 65	550,898		(466,693)	84,270
Balance as of end of period (in shares) at Jun. 30, 2021	64,770,219
Balance as of beginning of period at Dec. 31, 2021	$ 66	559,126		(542,388)	16,804
Balance as of beginning of period (in shares) at Dec. 31, 2021	65,500,275
Stockholders' Equity
Exercise of stock options		3			3
Exercise of stock options (in shares)	5,088
Issuance of common stock for vested restricted stock units (in shares)	198,244
Issuance of common stock to satisfy deferred purchase consideration	$ 7	7,929			7,936
Issuance of common stock to satisfy deferred purchase consideration (in shares)	6,815,072
Issuance of common stock under employee stock purchase plan		160			160
Issuance of common stock under employee stock purchase plan (in shares)	155,106
Stock-based compensation expense		4,596			4,596
Change in fair value of investments			(1)		(1)
Net loss				(61,052)	(61,052)
Balance as of end of period at Jun. 30, 2022	$ 73	571,814	(1)	(603,440)	(31,554)
Balance as of end of period (in shares) at Jun. 30, 2022	72,673,785
Balance as of beginning of period at Mar. 31, 2022	$ 73	569,974	(2)	(575,329)	(5,284)
Balance as of beginning of period (in shares) at Mar. 31, 2022	72,594,005
Stockholders' Equity
Issuance of common stock for vested restricted stock units (in shares)	79,780
Stock-based compensation expense		1,840			1,840
Change in fair value of investments			1		1
Net loss				(28,111)	(28,111)
Balance as of end of period at Jun. 30, 2022	$ 73	$ 571,814	$ (1)	$ (603,440)	$ (31,554)
Balance as of end of period (in shares) at Jun. 30, 2022	72,673,785